178 results about "Myeloid tissue" patented technology

An automatic method for analyzing nucleated bone marrow cells comprising partitioning one sample of bone marrow fluid with two samples, one sample being treated with a first lysing agent and a first staining solution and the other sample being treated with a second lysing agent and a second staining solution; and measuring each samples in a flow cytometer using a scattered light and fluoresence which enables to classify and count leukocytes, erythroid cells and lipid particles, as well as mature myeloid cells, lymphoid cells and immature myeloid cells, and to calculate the number of myeloid cells as well as the ratio of myeloid cells and erythroid cells.

The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.

The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and / or treatment of neoplastic disorders and diseases.

Methods for obtaining multipotent Apelin receptor-positive lateral plate mesoderm cells, mesenchymal stem cells, and mesangioblasts under serum-free conditions are disclosed.

The present invention relates to a periplaneta americana extract effective part with cytotoxic activity, a preparation method and a medical purpose thereof. The periplaneta americana extract effective part of the present invention is refined from fresh or dry blattidae periplaneta americana body which is extracted by alcohol water, processed for macroporous resin column chromatography and is eluted by alcohol solvent. The periplaneta americana extract effective part obtained by the present invention has obvious cytotoxicity and internal anticancer efficacy towards oral epidermoid carcinoma (KB) cell, poorly differentiated gastric abenocarcinoma tumour (BGC-823) cell, human chronic myelogonium leukaemia cancer (K562) cell and human myelogonium leukaemia cancer cell (HL-60) and can be used for preparing for a drug and a health care product for remedying the tumours.

The present invention is based on the discovery that teeth primordia can be generated using bone marrow cells and that bone marrow cells may be employed to generate teeth without the need for purification and expansion of a population of cells.

The invention provides a method for obtaining a hemopoietic stem cell by using a three-dimensional induction system. A three-dimensional cell culture medium or cell culture bracket, such as a three-dimensional cell culture system made of the materials such as hydrogel, seaweed and the like is utilized, and / or combined with matrix cells such as bone marrow cell, mouse bone marrow cell lines OP9, OP9DL1 and the like, and / or combined with a plurality of factors including mesoderm induction factors, hematopoietic growth factor and the like to induce multipotent stem cells to differentiate into hemopoietic stem cells. A new method for obtaining the hemopoietic stem cells is built. The system for efficiently inducing the multipotent stem cells to differentiate into the hemopoietic stem cells by using a three-dimensional induction system and / or combining with matrix cells such as bone marrow cell and the like and / or a plurality of factors is built for the first time. Theoretical basis and a technology platform are provided for obtaining clinically available hemopoietic stem cells, and a new method and a new concept are developed for application of hematopoietic cells derived from multipotent stem cells in the fields such as disease mechanism exploration, drug screening and the like.

A method of acquiring an image biomarker suitable for prognosis of a blood-related disease, such as acute myeloid leukemia, includes the steps of: (a) acquiring physical parameter sets, each including at least two physical parameters, respectively from time-signal intensity curves, the time-signal intensity curves being respectively obtained from magnetic resonance image sets of different subjects that are diagnosed as having the blood-related disease, each of the image sets being acquired through MRI scanning using one of first and second configuration parameter sets; (b) analyzing the physical parameter sets thus acquired with reference to prognoses of the different subjects so as to obtain weight values corresponding to the physical parameters; and (c) establishing a risk score function that is a sum of products of each of the physical parameters and the corresponding weight value, wherein a risk score obtained using the risk score function serves as the image biomarker suitable for prognosis of the blood-related disease.

The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.

The invention discloses a fly maggot extractive containing the principal components of water-soluble proteins, and the water-soluble proteins contained in the fly maggot extractive have the mass percentage of 50-70 percent and the molecular weight of 2-16 KDa. The fly maggot extractive not only has obvious inhibiting effect on human promyelocytic leukemia HL-60 cells, human erythroleukemia K562 cells, human liver cancers SMMC-7721, mouse leukemia P388 cells, human lung adenocarcinoma A549 cells, human nasopharyngeal darcinoma CNE cells, human prostatic carcinoma PC3 cells, human cervical carcinoma HeLa in vitro, but also has outstanding inhibiting effect on mouse S180 sarcomas and mouse Heps liver cancer solid tumors, and also has the effect on enhancing the humoral immunity of organisms. The invention also discloses a preparation method of the fly maggot extractive. The preparation method is easy and convenient for operation and control and low in cost and is suitable for industrialized production.

The invention relates to a kit for the rapid joint detection of epidemic JEV (Japanese Encephalitis Virus), DEV (Dengue Virus) and WNV (West Nile Virus). The kit consists of a main reaction solution and specific primers, wherein, the main reaction solution comprises a reaction buffer, AMV (Avian Myeloblastosis Virus) reverse transcriptase, a nuclease inhibitor, Bst (Bacillus stearothermophilus) DNA polymerase, dNTP (deoxyribonucleoside triphosphate), magnesium sulfate, betaine and DEPC (diethylpyrocarbonate) and conditioning water; and the specific primers comprise a specific amplification primer of JEV (PJEV), a specific amplification primer of DEV (PDV) and a specific amplification primer of WNV (PWNV). The invention is capable of rapidly detecting three viruses of flaviviridae by employing the LAMP (Loop-mediated Isothermal Amplification) technology and designing high-degree specific primers, thereby achieving the purpose of highly-efficient specific amplification. The invention further provides a detection method in which an ultraviolet-visible spectrophotometer is utilized for detecting the absorbance value of the reaction system and for indirectly reflecting the DNA amplification of target genes. Therefore, the invention is applicable to rapid detection at primary and field levels and is of greater application value.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-AB / C, ICOS-L, and CD58, and wherein the one or more viral vectors comprise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and / or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and / or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.

The present invention describes the cloning and molecular and cellular characterization of a novel protein with homology to the IL-17 receptor. The gene was cloned by virtue of its proximity to a common site of retroviral integration in a murine acute myeloid leukemia. The gene described herein possibly codes for a novel interleukin receptor that binds an as yet unidentified cytokine ligand, and may be useful in cancer diagnostics and therapies that rely on immune system modulation.

The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and / or treatment of neoplastic disorders and diseases.

The invention belongs to the technical field of gene engineering, and discloses a primer combination for detecting gene mutation related to AML (acute myeloid leukemia) prognosis, a kit containing the primer combination and a method for detecting gene mutation related to AML prognosis. The primer combination covers all hotspot mutant sites of FLT3, NPM1, DNMT3A and CEBPA genes, and has the advantages of high specificity and wide covering range. The annealing temperatures of all the primers are close, so that the amplification stage can be completed at one time by one procedure, and the hotspot mutation can be subjected to combined parallel detection; and the detection efficiency is high. Besides, the forward and reverse amplification primers are adopted to directly carry out sequencing, and software is utilized to directly carry out mutation analysis, so that the method has the advantages of visual detection and low cost, thereby providing important references for therapeutic scheme determination and prognosis judgment of AML.

The present invention provides HLA-restricted antigens as vaccines for treating or preventing autoimmune diseases or conditions, translpant rejection or vasculitis in a patient. In particular aspects, there is provided Pr3, a myeloid tissue-restricted protein and a HLA-A2.1-restricted self-peptide, PR1, derived from Pr3, which can be used to elicit PR1-specific CTLs. The present invention also provides a HLA-restricted-peptide myeloperoxidases-based methods.

The present invention describes the cloning and molecular and cellular characterization of a novel protein with homology to the IL-17 receptor. The gene was cloned by virtue of its proximity to a common site of retroviral integration in a murine acute myeloid leukemia. The gene described herein possibly codes for a novel interleukin receptor that binds an as yet unidentified cytokine ligand, and may be useful in cancer diagnostics and therapies that rely on immune system modulation.

A highly sensitive method of analyzing a sample for the presence or activity of botulinum neurotoxin (BoNT) or antibodies specific for botulinum neurotoxin is disclosed. In one embodiment, the method comprises the steps of preparing primary non-human mammalian or avian spinal cord cells, and exposing the cells to a test sample, in parallel with a control sample, and examining the extent of cleavage of the intracellular neuronal target protein in both the test and control sample.

The invention discloses a myeloid tissue plastic embedding and pelletizing method which comprises the processes of fixing, deliming, dehydrating, soaking, embedding, slicing and dyeing, wherein, the processes of fixing, deliming, dehydrating and soaking are carried out under ultrasonic high frequency resonance. Compared with the traditional plastic embedding and pelletizing method, the plastic embedding and pelletizing method shortens the time from 50 hours to 15 hours approximately, saves about 3 working days and reduces the time for plastic embedding and pelletizing greatly, thereby reducing the economic burden of the patient and gaining precious time for remedying.

The invention discloses a novel BH3 analogue targeted to Bcl-2 family anti-apoptotic protein and application of the novel BH3 analogue. The structural general formula of the BH3 analogue is as shown in the general formula A (the general formula A can be found in specification). A thought and method of peptidomimetics is adopted, the structure of a natural BH3 peptide fragment is simplified or modified, and the novel BH3 analogue is obtained. It is proved by experiments that the compound as shown in the general formula A and the Bcl-2 family anti-apoptotic protein represent excellent binding activity on the aspect of the molecular level; and it is shown by in-vitro carcinoma cell growth inhibition experiments that the compound has a certain in-vitro growth inhibition function on the human chronic myeloid leukemia cell K562, the human promyelocytic lenukemia cell HL-60 and the human tissue cell lymphoma cell U937. It is prompted by research results that the compound can be used as a candidate drug for preventing or treating related diseases caused by expression abnormality of anti-apoptotic protein in the Bcl-2 family protein.

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid / myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1 / A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and / or expression levels.

The invention relates to the technical field of biology, in particular to a leukemia mouse model based on a gene co-transfection technology and a preparation method thereof. The preparation method of the leukemia mouse model comprises the following steps: performing construction and packaging of K-ras mutants and AML1-ETO fusion gene lentivirus vectors; performing bone marrow cell separation and virus infection condition monitoring; implanting infection cells in a mouse to build a leukemia animal model; and performing model identification. The method of building the leukemia mouse model in a mode of utilizing caudal vein injection to lead in the manual site-directed mutagenesis K-ras mutants and AML1-ETO fusion gene lentivirus vectors is adopted initiatively. The leukemia mouse model is high in success rate, pathological characteristics are high in similarity to morbidity conditions of clinical leukemia, and the novel animal model can be provided for leukemia extramedullary infiltration mechanism research, leukemia medicine screening and gene and molecule target treatment.

The invention discloses a molecular marker with a CCDC72 gene for diagnosing the multiple myeloma. An experiment shows that compared with a normal myeloid tissue, the CCDC72 gene has a large expression quantity in a multiple myeloma tissue. The invention further discloses application of the CCDC72 gene in preparation of a medicine for treating the multiple myeloma. The research achievement provides a novel clinical multiple myeloma diagnosis method, and also provides a novel medicine target for treating the multiple myeloma.

The invention provides a compound tussah pupa powder food with an anti-radiation function. The compound tussah pupa powder food is characterized by comprising full tussah pupa powder, mung bean embryo, Tuckahoe, agaric, black sesame and brown sugar; and the manufacturing process comprises the following steps of: pre-treating the tussah pupa; pre-treating the mung bean embryo; carrying out freeze drying on the mung bean embryo and the tussah pupa; respectively drying the Tuckahoe, the agaric and the black sesame; respectively crushing the full tussah pupa powder, the mung bean embryo, the Tuckahoe, the agaric, the black sesame and the brown sugar; and uniformly mixing the ingredients in parts by weight to obtain a finished product. The compound tussah pupa powder food has the advantages of scientific and reasonable formulation and no toxic and side effect; after taken by mice, the compound tussah pupa powder food is verified and shown that the micro nuclear rate in the mouse bone marrow cell is obviously reduced, the peripheral white blood cell count and bone marrow cell DNA content are obviously increased and obvious auxiliary protection effects on the radiation hazard are obtained; the manufacturing process has the advantages of simplicity, short process, convenience in operation and control and low cost; and the nutrient components of the compound tussah pupa powder food can be kept.

This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and / or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.

The invention discloses a morphological feature fused microscopic image bone marrow cell counting method and system, and the method comprises the steps: 1) obtaining labeled and unlabeled bone marrow cell microscopic images, and carrying out the image preprocessing; 2) segmenting the labeled / label-free bone marrow cell microscopic image into a plurality of labeled / label-free single bone marrow cell microscopic images according to the cell segmentation marks and a watershed algorithm, and carrying out image preprocessing on the single bone marrow cell microscopic images; 3) carrying out cell nucleus and cytoplasm segmentation on the labeled and unlabeled single bone marrow cell microscopic images by using an improved maximum between-cluster variance method and an N-distance edge expansion method, and extracting morphological characteristics; 4) constructing a hybrid convolutional neural network model, and inputting the labeled single bone marrow cell microscopic image into the model for training; and 5) predicting cell categories of the unlabeled single bone marrow cell microscopic image by using the trained hybrid convolutional neural network model, and counting each cell category. The method has relatively high precision on bone marrow cell counting.

The present invention relates to a method for inducing differentiation myeloid-derived suppressor cells from cord blood CD34 positive cells and proliferating the same, and a use of the myeloid-derived suppressor cells. More specifically, myeloid-derived suppressor cells are induced to differentiate and proliferated by culturing cord blood CD34 positive cells in the presence of a cytokine cocktail of GM-CSF and SCF, such that myeloid-derived suppressor cells can be mass-produced in vitro, and the myeloid-derived suppressor cells can be used in preventing or treating immunorejection-related diseases such as graft-versus-host disease.

The invention discloses a continuous mature stage bone marrow cell image automatic identification method and system, and a medium. The method mainly comprises the following steps: obtaining a data set conforming to a specification; constructing a dense connection type convolutional neural network model for automatic identification of bone marrow cells through transfer learning; carrying out size normalization on the single-cell image data, and dividing a data set after image size normalization; finely adjusting hyper-parameters of the training method, performing structural parameter training on the constructed model through fine-adjusted hyper-parameter training, obtaining an optimal structural parameter model, and introducing multiple types of random data augmentation in training; and carrying out bone marrow cell recognition effect test and evaluation on the model by utilizing multi-fold cross validation. According to the invention, automatic identification or classification of the bone marrow cells in the continuous maturation stage can be realized, the identification effect is good, and the performance and accuracy of automatic identification of the bone marrow cells in the continuous maturation stage can be improved.